Hans Haltmayer

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

First German-speaking harm reduction conference in Vienna.

First German-speaking harm reduction conference in Vienna.

Journal: Harm reduction journal

Published: July 13, 2023

CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers.

CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers.

Journal: Journal of virus eradication

Published: March 01, 2023

Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy.

Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy.

Journal: Journal of virus eradication

Published: September 20, 2022

Towards an International Consensus on the Prevention, Treatment, and Management of High-Risk Substance Use and Overdose among Youth.

Towards an International Consensus on the Prevention, Treatment, and Management of High-Risk Substance Use and Overdose among Youth.

Journal: Medicina (Kaunas, Lithuania)

Published: March 04, 2022

Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.

Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.

Journal: PloS one

Published: January 19, 2021

Retention in the Austrian opioid agonist treatment system: a national prospective cohort study.

Retention in the Austrian opioid agonist treatment system: a national prospective cohort study.

Journal: Harm reduction journal

Published: November 20, 2020

Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria.

Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria.

Journal: PloS one

Published: October 08, 2019

Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.

Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.

Journal: European journal of gastroenterology & hepatology

Published: November 10, 2017

Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals.

Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals.

Journal: Journal of viral hepatitis

Published: August 30, 2017

Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy.

Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy.

Journal: The American journal of gastroenterology

Published: June 03, 2016

Showing 1-10 of 10

Last Updated: 09/26/2026